Printer Friendly

Propanc Biopharma Provides Update on Preparation of PRP for Clinical Trial Application Submission and Recently Completed Reverse Stock Split.

M2 PHARMA-July 16, 2019-Propanc Biopharma Provides Update on Preparation of PRP for Clinical Trial Application Submission and Recently Completed Reverse Stock Split

(C)2019 M2 COMMUNICATIONS

- Australia-based biopharmaceutical company Propanc Biopharma, Inc. (OTC: PPCBD) has provided an update on its preparation of PRP, its anti-cancer lead product candidate, for clinical trial application submission and its recently completed reverse stock split, the company said.

Propanc plans to submit its first clinical trial application in the second half of 2019, followed by commencement of a First-In-Human study in advanced cancer patients for PRP during the first half of 2020.

Approximately 80% of cancers are from solid tumors and metastasis is the main cause of patient death. PRP targets cancer stem cells which are resistant to standard treatments, remain dormant for long periods, then migrate to other organs, triggering explosive tumor growth and causing patient relapse. PRP is the mixture of two proenzymes (trypsinogen and chymotrypsinogen) from bovine pancreas.

A synergistic ratio of these proenzymes inhibits growth of most tumor cells. Efficacy has been shown in pancreatic, kidney, breast, brain, prostate, lung, liver, uterine, and skin cancers. Proenzyme therapy targets cancer stem cells not killed by radiation and chemotherapy.

PRP addresses the global, unmet medical need for combating solid tumor recurrence and metastasis.

In addition, Propanc's 1-for-500 reverse stock split of its shares of common stock was consummated in the market at the open of business on June 24, 2019, and the company's shares are now trading on the OTCQB on a post-split adjusted price. In connection with the split, Propanc's trading symbol temporarily changed to "PPCBD."

That "D" in Propanc's current trading symbol will remain for 20 business days until approximately July 22, 2019, after which the company's trading symbol will revert to its original symbol, "PPCB."

Propanc Biopharma is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers.

The company's novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body's primary defense against cancer.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 16, 2019
Words:376
Previous Article:Recursion Pharmaceuticals Secures USD 121m in Series C Financing.
Next Article:AVROBIO expects USD120.25m from public offering of common stock.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters